SEARCH

SEARCH BY CITATION

References

  • 1
    Testa MA, Simonson DC: Assessment of quality-of-life outcomes. N Engl J Med 1996; 334: 835840.”
  • 2
    Osoba D: Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 1994; 12: 608616.
  • 3
    Kornblith AB, Holland JC: Model for quality-of-life research from the Cancer and Leukemia Group B: The telephone interview, conceptual approach to measurement, and theoretical framework. J Natl Cancer Inst Monogr 1996; 20: 5562.
  • 4
    Fowler FJ Jr, Barry MJ, Lu-Yao G, et al: Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988–1990 (updated June 1993). Urology 1993; 42: 622629.
  • 5
    Jonler M, Messing EM, Rhodes PR, et al: Sequelae of radical prostatectomy. Br J Urol 1994; 74: 352358.
  • 6
    Geary ES, Dendinger TE, Stamey TA: Impotence, incontinence and vesical neck strictures following nerve-sparing radical prostatectomy. J Urol 1994; 151 (Suppl): 488A. Abstract.
  • 7
    Murphy GP, Mettlin C, Menck H, et al: National patterns of prostate cancer treatment by radical prostatectomy: Results of a survey by the American College of Surgeons Commission on Cancer. J Urol 1994; 152: 18171819.
  • 8
    Fowler FJ Jr, Barry MJ, Lu-Yao G, et al: Effect of radical prostatectomy for prostate cancer on patient quality of life: Result from a Medicare survey. Urology 1995; 45: 10071015.
  • 9
    Chodak GW, Sinner M, Rukstalis DB, et al: Patient-reported outcomes following radical prostatectomy performed at eight academic institutions. J Urol 1995; 153: 390. Abstract.
  • 10
    Skinner EC, Perez M, Lieskovsky G, et al: Quality of life following radical prostatectomy for carcinoma of the prostate. J Urol 1995; 153: 506. Abstract.
  • 11
    Litwin MS, Hays RD, Fink A, et al: Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129135.
  • 12
    McCammon KA, Schellhammer PF: Comparison of quality of life after radiation therapy or radical prostatectomy for localized carcinoma of the prostate. J Urol 1996; 155: 647. Abstract.
  • 13
    Thrasher JB, Kao T-C, Garner D, et al: Multicenter patient self-reported questionnaire of incontinence, impotence and quality of life after radical prostatectomy. J Urol 1996; 647. Abstract.
  • 14
    Talcott JA, Rieker P, Propert KJ, et al: Long-term complications of treatment for early prostate cancer: 2-year follow-up in a prospective, multi-institutional outcomes study. Proc Am Soc Clin Oncol 1996; 15: 252. Abstract.
  • 15
    Widmark A, Fransson P, Tavelin B: Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994; 74: 25202532.
  • 16
    Jonler M, Ritter MA, Brinkmann R, et al: Sequelae of definitive radiation therapy for prostate cancer localized to the pelvis. Urology 1994; 74: 876882.
  • 17
    Chinn DM, Holland J, Crownover RL, et al: Potency following high-dose three-dimensional conformal radiotherapy and the impact of prior major urologic surgical procedures in patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33: 1522.
  • 18
    Zincke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 18501857.
  • 19
    Braslis KG, Santa-Cruz C, Brickman AL, et al: Quality of life 12 months after radical prostatectomy. Br J Urol 1995; 75: 4853.
  • 20
    Mazur DJ, Merz JF: Older patients' willingness to trade off urologic adverse outcomes for a better chance at five-year survival in the clinical setting of prostate cancer. J Am Geriatr Soc 1995; 43: 979984.
  • 21
    Chapman GB, Bennett CL, Elstein AS: Prostate cancer patients' utilities for health states: A pilot study. Proc Am Soc Clin Oncol 1996; 15: 509. Abstract.
  • 22
    Simpson KN, Revicki DA, Qaqish BF, et al: Quality of life with clinically localized prostatic carcinoma: Prostatectomy versus watchful waiting. J Urol 1995; 153: 251. Abstract.
  • 23
    Cowen ME, Cahill D, Dattan MW, et al: The value or utility of prostate cancer states. J Urol 1996; 155: 376. Abstract.
  • 24
    Lu-Yao GL, Potosky AL, Albertson PC, et al: Follow-up prostate cancer treatments after radical prostatectomy: A population-based study. J Natl Cancer Inst 1996; 88: 166173.
  • 25
    Herr HW: Quality of life of incontinent men after radical prostatectomy. J Urol 1994; 151: 652654.
  • 26
    McLachlan SA, Tannock IF: The EORTC QLQ-C30 and utilities assessed by time trade-off (TTO) measure different aspects of health outcome in women with metastatic breast cancer. Proc Am Soc Clin Oncol 1996; 15: 509. Abstract.
  • 27
    Kornblith AB, Herr HW, Ofman US, et al: Quality of life of patients with prostate cancer and their spouses: The value of a data base in clinical care. Cancer 1994; 73: 27912802.
  • 28
    Klein CE, Prochazka A, Spitzer AL, et al: Spousal report of quality of life in treatment for localized prostate cancer. Proc Am Soc Clin Oncol 1996; 15: 508. Abstract.
  • 29
    Herr HW, Kornblith AB, Ofman U: A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 1993; 71 (Suppl 3): 11431150.
  • 30
    Herr HW: Quality of life of prostate cancer patients on or off hormone therapy. Proc Am Soc Clin Oncol 1995; 14: 231. Abstract.
  • 31
    Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265269.
  • 32
    Klotz LH, Herr HW, Morse MJ, et al: Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 25462550.
  • 33
    Goldenberg SL, Bruchovsky N, Gleave ME, et al: Intermittent androgen suppression in the treatment of prostate cancer. J Urol 1995; 153: 448. Abstract.
  • 34
    Bales GT, Sinner MD, Kim JH, et al: Impact of intermittent androgen deprivation on quality of life. J Urol 1996; 155: 578. Abstract.
  • 35
    Fossa SD, Aaronson NK, Newling D, et al: Advanced hormone resistant prostatic cancer: Preliminary observations on subjective morbidity and palliation. Eur Urol 1990; 18 (Suppl 1): 2. Abstract.
  • 36
    Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7: 590597.
  • 37
    Tannock I, Osoba D, Ernst S, et al: Chemotherapy with mitoxantrone and prednisone palliates patients with hormone-resistant prostate cancer. Proc Am Soc Clin Oncol 1995; 14: 245. Abstract.
  • 38
    Kantoff PW, Conaway M, Picus WE, et al: Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1996; 15: 1748. Abstract.
  • 39
    Stockler M, Osaba D, Goodwin P, et al: Validation of the PROSQOLI: A pragmatic outcome measure for clinical trials in advanced prostate cancer. Proc Am Soc Clin Oncol 1995; 14: 244. Abstract.
  • 40
    Spiegel D: Psychosocial intervention in cancer. J Natl Cancer Inst 1993; 85: 11981205.